Navigation Links
KemPharm's KP201 to be Featured at PAINWeek 2013
Date:8/28/2013

NORTH LIBERTY, Iowa, Aug. 28, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present a poster on KP201 at PAINWeek 2013, the nation's largest pain conference for frontline clinicians with an interest in pain management.  

The poster, entitled "KP201: A Novel Opioid Pain Therapy with Reduced Abuse Potential and Improved Safety," will be displayed on September 6, 2013 between 6:15 PM and 7:30 PM, PDT and will detail KP201's clinical studies and unique abuse-deterrent properties, which have been shown to significantly limit narcotic exposure upon intranasal administration and intravenous injection.  Additionally, the poster will highlight the potential for KP201 to prevent or reduce opioid-induced constipation (OIC).

Dr. Mickle commented, "Showcasing KP201 at PAINWeek 2013 provides an opportunity for clinicians with an interest in pain management to gain an understanding of the drug's advantages and its potential as a future treatment option for their patients.  We welcome the opportunity to present what we believe is very compelling data on KP201 that highlight not only its ability to treat pain but the added benefit of a reduction in abuse potential and opioid-induced constipation."

About KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.com.For KemPharm, Inc:Media / Investor Contacts:Christal Mickle

319-665-2575

info@kempharm.comJason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.827.0020

jrando@tiberend.com

jdrumm@tiberend.com  


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
2. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
3. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
4. Millennium HealthCare Inc. Featured in Forbes
5. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
6. Mid-Atlantic Biotech Leaders Featured On BioSpace Map
7. B. Braun Smart Infusion Pump Technology to be Featured in Integrating the Healthcare Enterprise (IHE) Interoperability Demonstration at AAMI 2013
8. Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting
9. AVTs Customer Medbox, Inc. Featured in Bloomberg Businessweek
10. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
11. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence. ... ... ... ... Sino-German High-Tech ...
(Date:5/3/2016)... Ore. , May 3, 2016   BIOTRONIK ... importance of extending care beyond the implant at the ... May 4-7 in San Francisco . ... continually delivering the highest quality of patient care and ... are cared for each and every tomorrow," said ...
Breaking Medicine Technology:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... A recent ... continue to face challenges in getting employees to understand and use the free preventive ... of the nation’s leading non-profit business groups of large, self-insured public and private employers, ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... has found that more than 40 percent of participating fifth-grade students already have ... of Allergy and Asthma Clinical Research in the Division of Pulmonary, Allergy and ...
(Date:5/5/2016)... ... 2016 , ... Sun Health registered nurse Brittany Eads and ... Care Transitions program at the 9th Annual Orthopedic and Spine Summit held ... Post-Acute Environment Through Effective Transitions of Care.” , Major changes are taking place ...
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs (TTL) is ... eve of National Nurses Week (May 6-12). Currently, HireNurses is a job ... enrollment into the Talent Tech Lab Virtual Incubation program, they will dramatically expand the ...
(Date:5/5/2016)... ... May 05, 2016 , ... The Lung Institute will celebrate its three-year anniversary on ... most clinic locations throughout the month of May. To date, the Lung Institute has treated ... that we’ve seen is a testament to the success of this treatment and to the ...
Breaking Medicine News(10 mins):